Stride Kai, Understanding Your Options
GLP-1 medications like Ozempic and Wegovy have produced results that genuinely surprised the medical community. People who had struggled with weight for decades saw meaningful, rapid change. The drugs work. Nobody serious disputes that.
What happens after is a different conversation. One that the prescribing industry has been slower to have than the patients who are living it.
A January 2026 analysis published in the British Medical Journal reviewed 37 studies covering around 9,300 people who had used 13 different weight-loss medications including semaglutide. The findings were stark.
People taking the most common GLP-1 drugs lost an average of 33 pounds while on treatment. Within a year of stopping, they regained an average of 22 pounds. And critically, they regained that weight approximately four times faster than people who had lost weight through diet and exercise alone.
A separate 2026 systematic review in eClinicalMedicine looked at data from 48 studies and reached a similar conclusion: participants regained roughly 60% of the weight they had lost on GLP-1 drugs within a year of stopping them.
The reason is straightforward. GLP-1 medications work by suppressing appetite and slowing stomach emptying. When you stop taking them, those effects stop too. Hunger returns. The metabolic advantages conferred by the drug disappear. And if no lifestyle habit has been built underneath, the body returns to where it was.
Weight regain is concerning. What comes back with it is potentially more so.
Clinical trials have shown that GLP-1 medications can lead to up to 13.9% loss of lean muscle mass during treatment. A 2024 study found that between a quarter and a third of total weight lost on Ozempic is lean mass, meaning muscle, not just fat. When that weight comes back after stopping, it comes back predominantly as fat, not as the muscle that was lost.
This matters because muscle is metabolically active tissue. It burns calories at rest. It supports bone density. It protects against the risk of injury and fall as we age. Losing it quietly during weight loss treatment and then not replacing it is a problem that unfolds over years, not weeks.
This is the part that most coverage of Ozempic doesn't reach. A 2024 clinical study found something important: people who exercised consistently while taking GLP-1 medications kept off significantly more weight after stopping than those who didn't exercise. They also lost less muscle during treatment.
The ACSM, the American College of Sports Medicine, published research confirming this directly: individuals who maintained a workout routine during GLP-1 treatment saw higher fat loss and lean mass preservation after stopping medication than those who relied on the drug alone.
Exercise doesn't just add to the results. It appears to change the nature of the weight loss itself, protecting muscle, improving metabolic rate, and creating the habit infrastructure that gives the body somewhere to go after the drug is stopped.
The FDA recommends that people taking GLP-1 medications for weight loss also follow a diet and exercise program. Not as a bonus. As a core part of treatment. Walking is specifically cited as one of the most effective forms of low-impact exercise during GLP-1 therapy, accessible, non-exhausting, and highly effective for cardiovascular health and fat burning without overtaxing a body adjusting to reduced caloric intake.
When appetite is suppressed and calories are reduced, high-intensity exercise can feel genuinely difficult. The body has less fuel. Recovery takes longer. The risk of doing too much and burning out is real.
This is precisely why walking, done correctly, has become the exercise most consistently recommended alongside GLP-1 treatment. It's low impact. It's sustainable daily. It doesn't require recovery time. And when combined with the right method, it produces cardiovascular and metabolic benefits that support the drug's goals rather than competing with them.
The phrase "done correctly" is doing important work in that sentence. A casual 20-minute stroll at steady pace produces modest benefits. The interval walking method developed by Dr. Hiroshi Nose at Shinshu University in Japan, alternating fast and slow walking at precise intervals for 30 minutes, produces dramatically better outcomes: more fat burned, greater cardiovascular improvement, better blood pressure results, and critically, a habit that participants actually maintained for months after the study ended.
That last point matters enormously for anyone on GLP-1 therapy. The drug creates the window. The habit is what keeps the results when the window closes.
Research consistently shows that around 50% of people stop taking GLP-1 medications within twelve months. The reasons vary: cost, side effects, reaching a goal weight, access issues, or simply choosing to stop. Whatever the reason, stopping is common. And the evidence is clear that what someone was doing before they stopped determines much of what happens next.
Building a consistent walking habit during treatment, one that becomes automatic rather than effortful, is the thing most likely to protect the results after the medication ends. Not because walking alone equals the drug's effects. But because a body that has been moving consistently, building cardiovascular fitness, preserving muscle, and training its metabolism to work efficiently, responds very differently to stopping treatment than one that hasn't.
Stride Kai guides Dr. Nose's exact interval walking protocol with audio and vibration cues. Low impact enough to do daily alongside any treatment. Effective enough to build the metabolic foundation that keeps results long after anything else changes. Free 3-day trial.
Not definitely, but the research suggests it's likely without sustained lifestyle changes. The 2026 BMJ analysis found most people regained significant weight within a year of stopping. However, those who had built exercise and dietary habits during treatment fared considerably better. A newer 2026 Cleveland Clinic study of nearly 8,000 patients found a more hopeful picture when people either restarted treatment, switched medications, or had adopted genuine lifestyle changes.
Clinical trials have shown up to 13.9% loss of lean muscle mass during semaglutide treatment. This is partly a natural consequence of rapid weight loss through any method, with roughly a quarter to a third of lost weight typically being lean mass. Regular exercise, particularly resistance training and walking, is the primary intervention recommended to reduce muscle loss during treatment.
Medical guidance consistently recommends a combination of resistance training two to three times per week to preserve muscle, and low-impact aerobic exercise daily for cardiovascular health and fat burning. Walking is specifically recommended as highly effective and accessible without overtaxing a body adjusting to reduced caloric intake. The Japanese interval walking method is particularly well suited because it produces superior cardiovascular and fat-burning results compared to steady-pace walking, at the same low-impact level.
Yes, and it's strongly encouraged. The FDA recommends exercise as part of any GLP-1 treatment plan. Always consult your prescribing doctor before beginning or changing any exercise routine, particularly if you have underlying health conditions.
Sources: British Medical Journal (January 2026), eClinicalMedicine systematic review (2026), ACSM Top Fitness Trends Report (2026), Drugs.com medical review (February 2026), Hinge Health clinical review (2026). This article is for informational purposes only and is not a substitute for medical advice.
Related reading: The Japanese Walking Method, what it is and why it works · Does the Fitbit actually help you lose fat?